
  
    
      
        Introduction_NNP
        Worldwide_NNP approximately_RB 40_CD million_CD people_NNS are_VBP infected_VBN with_IN HIV_NNP ,_, and_CC more_JJR than_IN 3_CD million_CD
        people_NNS died_VBD of_IN AIDS_NNP last_JJ year_NN alone_RB [_NN 1_CD ]_NN ._. Unfortunately_RB ,_, numerous_JJ obstacles_NNS to_TO providing_VBG
        effective_JJ antiretroviral_NN treatment_NN to_TO the_DT majority_NN of_IN infected_JJ individuals_NNS in_IN resource-poor_JJ
        countries_NNS exist_VBP ._. The_DT development_NN of_IN a_DT vaccine_NN or_CC other_JJ preventive_JJ biomedical_JJ intervention_NN
        therefore_RB bears_VBZ the_DT greatest_JJS hope_VBP to_TO curb_VB the_DT rampant_JJ HIV_NNP epidemic_NN [_NN 2_CD ]_NN ._.
        Research_NNP on_IN HIV_NNP vaccines_NNS and_CC prevention_NN relies_VBZ strongly_RB on_IN preclinical_JJ studies_NNS in_IN
        macaque_NN models_NNS for_IN the_DT identification_NN and_CC evaluation_NN of_IN potential_JJ vaccines_NNS or_CC prophylactic_JJ
        treatment_NN strategies_NNS [_NN 3_CD ]_NN ._. Initially_RB ,_, the_DT goal_NN was_VBD to_TO use_VB animal_NN trials_NNS to_TO screen_VB for_IN
        preventive_JJ interventions_NNS that_WDT induce_VB sterilizing_VBG immunity_NN (_( i_NNP ._. e_SYM ._. ,_, protection_NN against_IN
        infection_NN )_) since_IN this_DT would_MD clearly_RB be_VB the_DT most_RBS effective_JJ way_NN to_TO contain_VB the_DT AIDS_NNP pandemic_JJ ._.
        Unfortunately_RB ,_, most_JJS of_IN the_DT vaccine_NN approaches_NNS assessed_VBN to_TO date_NN in_IN animal_NN studies_NNS have_VBP
        failed_VBN to_TO induce_VB sterilizing_VBG immunity_NN [_NN 4_CD –_NN 7_CD ]_NN ,_, although_IN some_DT prophylactic_JJ approaches_NNS were_VBD
        found_VBN to_TO reduce_VB susceptibility_NN to_TO infection_NN [_NN 8_CD –_NN 12_CD ]_NN ._. As_IN a_DT result_NN of_IN this_DT shortcoming_NN ,_,
        vaccine_NN candidates_NNS are_VBP at_IN present_JJ primarily_RB examined_VBD with_IN regard_NN to_TO their_PRP$ effects_NNS on_IN set_VBN
        point_NN viremia_NN ,_, disease_NN progression_NN ,_, and_CC their_PRP$ general_JJ immunogenicity_NN ,_, rather_RB than_IN with_IN
        regard_NN to_TO the_DT degree_NN of_IN protection_NN against_IN infection_NN they_PRP confer_VBP ._. However_RB ,_, the_DT inference_NN as_IN
        to_TO the_DT degree_NN of_IN sterilizing_VBG immunity_NN from_IN the_DT level_NN of_IN immunogenicity_NN is_VBZ limited_VBN by_IN our_PRP$
        lack_NN of_IN knowledge_NN about_IN the_DT mechanisms_NNS of_IN protection_NN against_IN infection_NN as_IN such_JJ [_NN 13_CD ]_NN ._.
        The_DT inability_NN of_IN most_JJS vaccine_NN candidates_NNS to_TO induce_VB protection_NN against_IN infection_NN in_IN
        animal_NN studies_NNS may_MD be_VB due_JJ ,_, at_IN least_JJS in_IN part_NN ,_, to_TO unintended_JJ consequences_NNS of_IN the_DT design_NN of_IN
        the_DT animal_NN trials_NNS ,_, rather_RB than_IN to_TO problems_NNS inherent_JJ in_IN the_DT vaccination_NN approaches_NNS
        themselves_PRP ._. In_IN most_JJS animal_NN studies_NNS that_WDT seek_VBP to_TO test_VB the_DT efficacy_NN of_IN a_DT given_VBN preventive_JJ
        intervention_NN ,_, very_RB high_JJ challenge_NN doses_NNS are_VBP used_VBN ,_, typically_RB of_IN approximately_RB 10_CD –_NN 100_CD times_NNS
        the_DT infectious_JJ dose_NN at_IN which_WDT 50_CD %_NN of_IN the_DT animals_NNS become_VBP infected_JJ (_(
        ID_NNP
        50_CD )_) ._. The_DT motivation_NN for_IN using_VBG such_JJ high_JJ challenge_NN doses_NNS is_VBZ mostly_RB
        practical_JJ :_: the_DT experimenter_NN wants_VBZ to_TO ascertain_VB infection_NN success_NN in_IN unvaccinated_JJ /_NN untreated_JJ
        animals_NNS ,_, which_WDT can_MD then_RB be_VB compared_VBN to_TO the_DT hopefully_RB lower_JJR infection_NN success_NN in_IN
        vaccinated_JJ /_NN treated_VBD animals_NNS ._. There_EX are_VBP ,_, however_RB ,_, concerns_NNS with_IN using_VBG high_JJ challenge_NN doses_NNS ._.
        Firstly_NNP ,_, the_DT extremely_RB high_JJ probability_NN of_IN infection_NN in_IN high-dose_JJ challenge_NN studies_VBZ
        conflicts_NNS with_IN the_DT low_JJ transmission_NN rate_NN of_IN HIV_NNP per_IN sex_NN act_NN [_NN 14_CD –_NN 17_CD ]_NN ._. Although_IN it_PRP has_VBZ been_VBN
        argued_VBN that_IN transmission_NN rates_NNS may_MD be_VB higher_JJR under_IN some_DT circumstances_NNS (_( such_JJ as_IN during_IN acute_JJ
        infection_NN or_CC when_WRB other_JJ infections_NNS of_IN the_DT genital_JJ tract_NN are_VBP present_JJ )_) than_IN the_DT estimates_NNS
        obtained_VBN from_IN discordant_JJ couple_NN studies_NNS suggest_VBP (_( e_SYM ._. g_SYM ._. ,_, the_DT recent_JJ study_NN by_IN Pilcher_NNP et_CC al_NN ._.
        [_NN 18_CD ]_NN )_) ,_, transmission_NN of_IN HIV_NNP during_IN one_CD sex_NN act_NN surely_RB does_VBZ not_RB occur_VB with_IN certainty_NN ._.
        Secondly_RB ,_, protection_NN against_IN high-dose_JJ virus_NN challenges_NNS may_MD be_VB more_RBR difficult_JJ to_TO achieve_VB
        because_IN the_DT use_NN of_IN high_JJ challenge_NN doses_NNS makes_VBZ stochastic_JJ extinctions_NNS that_WDT can_MD play_VB an_DT
        important_JJ role_NN in_IN early_JJ control_NN of_IN the_DT infection_NN [_NN 19_CD ]_NN very_RB unlikely_JJ ._. Thus_RB ,_, standard_JJ
        high-dose_JJ challenge_NN studies_NNS may_MD rule_VB out_IN preventive_JJ intervention_NN strategies_NNS that_WDT could_MD
        protect_VB against_IN infections_NNS following_VBG “ real_JJ life_NN” exposures_NNS ._.
        The_DT problems_NNS of_IN using_VBG high_JJ virus_NN doses_NNS in_IN animal_NN studies_NNS can_MD be_VB illustrated_VBN by_IN the_DT
        discrepancy_NN between_IN the_DT protection_NN zidovudine_NN (_( AZT_NNP )_) confers_VBZ in_IN animals_NNS and_CC humans_NNS ._. Whereas_IN
        macaques_NNS [_NN 20_CD ,_, 21_CD ]_NN and_CC mice_NNS [_NN 22_CD ]_NN were_VBD not_RB protected_VBN from_IN infection_NN with_IN high_JJ challenge_NN doses_NNS
        by_IN zidovudine_NN (_( a_DT relatively_RB weak_JJ antiretroviral_NN drug_NN when_WRB used_VBN in_IN monotherapy_NN )_) ,_, clinical_JJ
        studies_NNS surprisingly_RB showed_VBD that_IN two-thirds_NNS of_IN perinatal_NN infections_NNS (_( i_NNP ._. e_SYM ._. ,_, mother-to-child_JJ
        transmissions_NNS during_IN birth_NN )_) can_MD be_VB prevented_VBN by_IN zidovudine_NN administration_NN [_NN 23_CD ]_NN ._. It_PRP is_VBZ
        important_JJ to_TO note_VB that_IN the_DT use_NN of_IN zidovudine_NN to_TO prevent_VB perinatal_NN HIV_NNP infection_NN is_VBZ a_DT
        biomedical_JJ intervention_NN aiming_VBG to_TO protect_VB from_IN infection_NN ,_, whereas_IN zidovudine_NN is_VBZ most_RBS
        commonly_RB used_VBN as_IN a_DT therapeutic_JJ agent_NN after_IN infection_NN ._. This_DT example_NN suggests_VBZ that_IN there_EX is_VBZ a_DT
        need_NN for_IN experimental_JJ designs_NNS that_WDT allow_VBP the_DT assessment_NN of_IN the_DT protection_NN against_IN infection_NN
        with_IN lower_JJR ,_, and_CC thus_RB more_RBR realistic_JJ ,_, challenge_NN doses_NNS ._.
        The_DT belief_NN that_IN experiments_NNS involving_VBG realistically_RB low_JJ challenge_NN doses_NNS require_VBP
        unfeasibly_RB large_JJ numbers_NNS of_IN animals_NNS has_VBZ prevented_VBN the_DT development_NN of_IN low-dose_JJ challenge_NN
        models_NNS ._. In_IN this_DT theoretical_JJ study_NN ,_, we_PRP show_VBP that_IN ,_, contrary_JJ to_TO this_DT widely_RB held_VBN belief_NN ,_,
        low-dose_JJ challenge_NN experiments_NNS can_MD be_VB designed_VBN such_JJ that_IN they_PRP do_VBP not_RB require_VB large_JJ numbers_NNS
        of_IN animals_NNS ._. Using_VBG statistical_JJ power_NN analysis_NN ,_, we_PRP compare_VBP two_CD experimental_JJ designs_NNS (_( see_VB
        Figure_NN 1_LS )_) :_: (_( i_NNP )_) a_DT single_JJ low-dose_JJ challenge_NN design_NN in_IN which_WDT each_DT animal_NN is_VBZ challenged_VBN only_RB
        once_RB ,_, and_CC (_( ii_NN )_) a_DT repeated_VBN low-dose_JJ challenge_NN design_NN in_IN which_WDT each_DT animal_NN is_VBZ challenged_VBN
        until_IN it_PRP is_VBZ infected_VBN or_CC a_DT predetermined_VBN maximum_NN number_NN of_IN challenges_NNS is_VBZ reached_VBN ._. We_PRP find_VBP
        that_IN the_DT repeated_VBN low-dose_JJ challenge_NN design_NN does_VBZ not_RB require_VB unfeasibly_RB large_JJ numbers_NNS of_IN
        animals_NNS ._.
        In_IN the_DT following_NN ,_, we_PRP are_VBP going_VBG to_TO discuss_VB the_DT case_NN of_IN assessing_VBG whether_IN a_DT vaccine_NN
        candidate_NN induces_VBZ sterilizing_VBG immunity_NN ._. All_DT the_DT considerations_NNS in_IN this_DT article_NN ,_, however_RB ,_,
        apply_VB equally_RB to_TO other_JJ preventive_JJ interventions_NNS ,_, such_JJ as_IN microbicides_NNS ._.
      
      
        Methods_NNP
        To_TO assess_VB the_DT quality_NN of_IN the_DT single_JJ and_CC the_DT repeated_VBN low-dose_JJ challenge_NN designs_NNS ,_, we_PRP
        conducted_VBD a_DT statistical_JJ power_NN analysis_NN ._. The_DT statistical_JJ power_NN of_IN an_DT experimental_JJ design_NN is_VBZ
        defined_VBN as_IN the_DT probability_NN that_IN an_DT effective_JJ vaccine_NN or_CC treatment_NN is_VBZ correctly_RB determined_VBN
        to_TO be_VB effective_JJ ._. This_DT analysis_NN consists_VBZ of_IN simulating_VBG the_DT experiments_NNS ,_, evaluating_VBG them_PRP ,_, and_CC
        then_RB repeating_VBG this_DT procedure_NN thousands_NNS of_IN times_NNS to_TO estimate_VB the_DT statistical_JJ power_NN of_IN a_DT
        given_VBN experimental_JJ design_NN ._.
        
          Simulation_NN of_IN Single_NNP Low-_NNP Dose_NNP Challenge_NNP Experiments_NNS
          In_IN our_PRP$ simulations_NNS of_IN the_DT single_JJ low-dose_JJ challenge_NN experiments_NNS ,_, we_PRP assume_VBP that_IN we_PRP
          have_VBP 
          n_NN unvaccinated_JJ control_NN animals_NNS and_CC 
          n_NN vaccinated_JJ animals_NNS ._.
          In_IN the_DT control_NN group_NN ,_, we_PRP simulate_VBP single_JJ challenges_NNS of_IN each_DT animal_NN with_IN the_DT 
          ID_NNP
          50_CD by_IN performing_VBG 
          n_NN Bernoulli_NNP trials_NNS with_IN a_DT probability_NN of_IN success_NN of_IN 
          p_NN
          c_SYM =_SYM 0_CD ._. 5_CD ._. The_DT probability_NN of_IN success_NN corresponds_NNS to_TO the_DT
          probability_NN with_IN which_WDT an_DT animal_NN becomes_VBZ infected_VBN after_IN a_DT single_JJ challenge_NN ._. (_( By_IN assuming_VBG
          the_DT same_JJ probability_NN 
          p_NN
          c_SYM for_IN each_DT animal_NN ,_, we_PRP ignore_VBP potential_JJ between-animal_JJ variation_NN
          of_IN the_DT susceptibility_NN to_TO infection_NN ._. This_DT assumption_NN will_MD be_VB relaxed_VBN below_IN ._. )_) The_DT results_NNS
          of_IN these_DT trials_NNS can_MD be_VB written_VBN as_IN a_DT vector_NN 
          
            x_SYM
          
          
          c_SYM ,_, the_DT entries_NNS of_IN which_WDT were_VBD either_CC zero_CD (_( uninfected_JJ )_) or_CC one_CD
          (_( infected_JJ )_) :_:
          
          By_IN summing_VBG over_IN the_DT elements_NNS of_IN 
          
            x_SYM
          
          
          c_SYM ,_, we_PRP obtain_VBP the_DT number_NN of_IN infected_JJ animals_NNS in_IN the_DT control_NN group_NN ,_,
          
          ι_NN
          c_SYM :_:
          
          In_IN the_DT vaccinated_JJ group_NN ,_, we_PRP simulate_VBP single_JJ challenges_NNS with_IN the_DT 
          ID_NNP
          50_CD similarly_RB to_TO the_DT control_NN group_NN by_IN performing_VBG Bernoulli_NNP trials_NNS ._.
          However_RB ,_, we_PRP assume_VBP that_RB ,_, because_IN of_IN vaccination_NN ,_, the_DT probability_NN of_IN infection_NN (_( or_CC
          success_NN )_) in_IN the_DT vaccinated_JJ group_NN ,_, 
          p_NN
          v_NN ,_, is_VBZ lower_JJR than_IN that_DT in_IN the_DT control_NN animals_NNS ,_, 
          p_NN
          c_SYM ._. The_DT relation_NN of_IN 
          p_NN
          v_NN to_TO the_DT effect_NN of_IN the_DT vaccine_NN on_IN the_DT susceptibility_NN of_IN the_DT host_NN ,_,
          
          VE_NNP
          S_NNP ,_, is_VBZ given_VBN by_IN :_:
          
          The_DT results_NNS of_IN these_DT Bernoulli_NNP trials_NNS can_MD again_RB be_VB written_VBN as_IN a_DT vector_NN 
          
            x_SYM
          
          
          v_NN ,_, and_CC summing_VBG the_DT elements_NNS of_IN 
          
            x_SYM
          
          
            v_NN
          we_PRP obtain_VBP the_DT number_NN of_IN infected_JJ animals_NNS in_IN the_DT vaccinated_JJ group_NN ,_, 
          ι_NN
          v_NN ._.
          The_DT outcome_NN of_IN the_DT simulated_JJ experiment_NN can_MD then_RB be_VB summarized_VBD in_IN a_DT contingency_NN table_NN
          as_IN shown_VBN in_IN Table_NNP 1_CD ._. On_IN this_DT contingency_NN table_NN ,_, we_PRP perform_VBP a_DT standard_JJ one-tailed_JJ Fisher_NNP 's_POS
          exact_JJ test_NN [_NN 24_CD ]_NN to_TO assess_VB whether_IN the_DT fraction_NN of_IN infected_JJ animals_NNS in_IN the_DT vaccinated_JJ
          group_NN is_VBZ significantly_RB lower_JJR than_IN that_DT in_IN the_DT control_NN group_NN ._.
        
        
          Simulation_NN of_IN Repeated_NNP Low-_NNP Dose_NNP Challenge_NNP Experiments_NNS
          In_IN our_PRP$ simulations_NNS of_IN the_DT repeated_VBN low-dose_JJ challenge_NN experiments_NNS ,_, we_PRP once_RB more_JJR assume_VB
          that_IN we_PRP have_VBP 
          n_NN unvaccinated_JJ control_NN animals_NNS and_CC 
          n_NN vaccinated_JJ animals_NNS ._.
          We_PRP again_RB simulate_VBP challenges_NNS of_IN each_DT control_NN animal_NN with_IN the_DT 
          ID_NNP
          50_CD by_IN performing_VBG Bernoulli_NNP trials_NNS with_IN a_DT probability_NN of_IN success_NN of_IN 
          p_NN
          c_SYM =_SYM 0_CD ._. 5_CD ._. Unlike_IN in_IN the_DT simulations_NNS of_IN the_DT single_JJ low-dose_JJ
          challenge_NN experiments_NNS ,_, however_RB ,_, we_PRP now_RB repeatedly_RB challenge_VB each_DT animal_NN until_IN it_PRP is_VBZ
          infected_VBN or_CC until_IN a_DT maximum_NN number_NN of_IN challenges_NNS ,_, 
          C_NNP
          max_NN ,_, has_VBZ been_VBN performed_VBN ._. We_PRP assume_VBP that_IN the_DT probability_NN of_IN
          infection_NN 
          p_NN
          c_SYM is_VBZ independent_JJ of_IN how_WRB often_RB an_DT animal_NN has_VBZ been_VBN challenged_VBN
          before_RB ._. The_DT results_NNS of_IN these_DT repeated_VBN Bernoulli_NNP trials_NNS can_MD be_VB written_VBN as_IN two_CD vectors_NNS ,_, 
          
            y_NN
          
          
          c_SYM ,_, which_WDT contains_VBZ the_DT number_NN of_IN challenges_NNS that_WDT have_VBP been_VBN
          performed_VBN on_IN each_DT animal_NN :_:
          
          and_CC 
          
            s_VBZ
          
          
          c_SYM ,_, which_WDT contains_VBZ information_NN on_IN whether_IN a_DT given_VBN animal_NN is_VBZ
          uninfected_JJ (_( zero_CD )_) or_CC infected_JJ (_( one_CD )_) :_:
          
          By_IN summing_VBG over_IN 
          
            y_NN
          
          
          c_SYM ,_, we_PRP obtain_VBP the_DT total_JJ number_NN of_IN challenges_NNS performed_VBN in_IN the_DT
          control_NN group_NN ,_, η_NN
          
          c_SYM :_:
          
          And_CC ,_, by_IN summing_VBG over_IN 
          
            s_VBZ
          
          
          c_SYM ,_, we_PRP obtain_VBP the_DT number_NN of_IN infected_JJ animals_NNS in_IN the_DT control_NN group_NN ,_,
          
          ι_NN
          c_SYM :_:
          
          To_TO simulate_VBP repeated_VBN low-dose_JJ challenges_NNS in_IN the_DT vaccinated_JJ group_NN ,_, we_PRP perform_VBP repeated_VBN
          Bernoulli_NNP trials_NNS with_IN a_DT probability_NN of_IN success_NN 
          p_NN
          v_NN ._. For_IN a_DT given_VBN vaccine_NN efficacy_NN 
          VE_NNP
          S_NNP ,_,
          p_NN
          v_NN is_VBZ determined_VBN by_IN equation_NN 3_CD ._. Analogously_NNP to_TO the_DT control_NN group_NN ,_,
          the_DT results_NNS of_IN these_DT repeated_VBN Bernoulli_NNP trials_NNS can_MD be_VB written_VBN as_IN two_CD vectors_NNS ,_, 
          
            y_NN
          
          
            v_NN
          and_CC 
          
            s_VBZ
          
          
          v_NN ,_, and_CC summing_VBG the_DT elements_NNS of_IN these_DT two_CD vectors_NNS yields_VBZ the_DT total_JJ
          number_NN of_IN challenges_NNS performed_VBN in_IN the_DT vaccinated_JJ group_NN ,_, η_NN
          
          v_NN ,_, and_CC ,_, the_DT number_NN of_IN infected_JJ animals_NNS in_IN the_DT vaccinated_JJ group_NN ,_, 
          ι_NN
          v_NN ._.
          As_IN in_IN the_DT case_NN of_IN the_DT single_JJ low-dose_JJ challenge_NN design_NN ,_, the_DT outcome_NN of_IN the_DT simulated_JJ
          experiment_NN can_MD be_VB summarized_VBD in_IN a_DT contingency_NN table_NN (_( Table_NNP 2_LS )_) ._. To_TO assess_VB whether_IN the_DT
          fraction_NN of_IN infected_JJ animals_NNS in_IN the_DT vaccinated_JJ group_NN is_VBZ significantly_RB lower_JJR than_IN that_DT in_IN
          the_DT control_NN group_NN ,_, we_PRP again_RB perform_VBP a_DT one-tailed_JJ Fisher_NNP 's_POS exact_JJ test_NN [_NN 24_CD ]_NN ._. In_IN general_JJ ,_,
          the_DT number_NN of_IN challenges_NNS ,_, η_NN
          
            c_SYM
          and_CC η_NN
          
          v_NN ,_, is_VBZ larger_JJR than_IN the_DT number_NN of_IN animals_NNS per_IN group_NN ,_, 
          n_NN ._. This_DT increase_NN of_IN numbers_NNS in_IN the_DT contingency_NN table_NN leads_VBZ to_TO
          increased_VB statistical_JJ power_NN of_IN the_DT repeated_VBN low-dose_JJ challenge_NN design_NN ._. To_TO analyze_VB the_DT
          outcome_NN of_IN the_DT simulated_JJ repeated_VBN low-dose_JJ challenge_NN experiments_NNS ,_, we_PRP chose_VBD to_TO use_VB
          Fisher_NNP 's_POS exact_JJ test_NN rather_RB than_IN a_DT more_RBR obvious_JJ Cox_NNP proportional_JJ hazards_NNS model_NN because_IN the_DT
          latter_JJ depends_VBZ on_IN large_JJ sample_NN asymptotics_NNS while_IN we_PRP were_VBD interested_JJ in_IN cases_NNS of_IN small_JJ
          numbers_NNS of_IN experimental_JJ animals_NNS ._.
        
        
          Heterogeneity_NNP in_IN Infection_NNP Probabilities_NNP
          In_IN our_PRP$ mml_NN :_: mathematical_JJ description_NN of_IN challenge_NN experiments_NNS ,_, we_PRP have_VBP assumed_VBN that_IN
          animals_NNS within_IN each_DT group_NN have_VBP equal_JJ infection_NN probabilities—_NN
          p_NN
          c_SYM and_CC 
          p_NN
          v_NN ,_, for_IN the_DT control_NN and_CC vaccinated_JJ groups_NNS ,_, respectively_RB ._. To_TO
          simulate_VBP potential_JJ animal-to-animal_JJ variation_NN in_IN susceptibility_NN to_TO infection_NN ,_, we_PRP relaxed_VBD
          this_DT assumption_NN and_CC assigned_VBN individual_JJ infection_NN probabilities_NNS to_TO each_DT animal_NN ._.
          The_DT individual_JJ infection_NN probabilities_NNS are_VBP drawn_VBN from_IN a_DT β-distribution_JJ ,_, which_WDT is_VBZ often_RB
          used_VBN as_IN a_DT prior_JJ distribution_NN for_IN binomial_NN proportions_NNS ._. The_DT β-distribution_JJ has_VBZ two_CD shape_NN
          parameters_NNS ,_, α_NN and_CC β_NN ._. Its_PRP$ probability_NN density_NN is_VBZ given_VBN by_IN
          
          and_CC its_PRP$ mean_NN and_CC variance_NN are_VBP
          
          
          We_PRP assume_VBP that_DT μ_NN =_SYM 
          p_NN
          c_SYM in_IN the_DT control_NN group_NN and_CC μ_NN =_SYM 
          p_NN
          v_NN =_SYM (_( 1_CD −_NN 
          VE_NNP
          S_NNP )_)
          p_NN
          c_SYM in_IN the_DT vaccinated_JJ group_NN ._. Further_RB ,_, we_PRP assume_VBP that_IN the_DT
          coefficients_NNS of_IN variation_NN ,_, 
          CV_NNP =_SYM σ_NN /_NN μ_NN ,_, of_IN the_DT distributions_NNS in_IN the_DT two_CD groups_NNS are_VBP equal_JJ ._. With_IN these_DT
          assumptions_NNS ,_, we_PRP can_MD rewrite_VB the_DT two_CD shape_NN parameters_NNS of_IN the_DT β-distribution_JJ ,_, α_NN and_CC β_NN ,_, in_IN
          terms_NNS of_IN the_DT infection_NN probability_NN ,_, 
          p_NN ,_, and_CC the_DT coefficient_NN of_IN variation_NN ,_, 
          CV_NNP :_:
          
          
          Hereby_NNP ,_, 
          p_NN =_SYM p_NN
          c_SYM for_IN the_DT control_NN group_NN and_CC 
          p_NN =_SYM p_NN
          v_NN =_SYM (_( 1_CD −_NN 
          VE_NNP
          S_NNP )_)
          p_NN
          c_SYM for_IN the_DT vaccinated_JJ group_NN ._.
          To_TO incorporate_VB potential_JJ heterogeneity_NN in_IN susceptibility_NN into_IN the_DT virtual_JJ low-dose_JJ
          challenge_NN experiments_NNS ,_, we_PRP replaced_VBD the_DT probability_NN of_IN success_NN in_IN the_DT Bernoulli_NNP trials_NNS
          (_( see_VB above_IN )_) with_IN the_DT individual_JJ infection_NN probabilities_NNS ._.
        
        
          Power_NNP Analysis_NNP
          To_TO calculate_VB the_DT statistical_JJ power_NN of_IN the_DT single_JJ and_CC the_DT repeated_VBN low-dose_JJ challenge_NN
          designs_NNS ,_, we_PRP performed_VBD 100_CD ,_, 000_CD such_JJ simulated_JJ experiments_NNS for_IN a_DT given_VBN number_NN ,_, 
          n_NN ,_, of_IN animals_NNS per_IN group_NN ._. The_DT statistical_JJ power_NN can_MD be_VB estimated_VBN as_IN the_DT
          fraction_NN of_IN simulated_JJ experiments_NNS in_IN which_WDT the_DT vaccine_NN is_VBZ found_VBN to_TO be_VB significantly_RB
          efficacious_JJ (_( significance_NN level_NN α_NN =_SYM 0_CD ._. 05_CD )_) ._. We_PRP estimated_VBD the_DT statistical_JJ power_NN for_IN the_DT
          number_NN of_IN animals_NNS per_IN group_NN ,_, 
          n_NN ,_, ranging_VBG from_IN one_CD to_TO 20_CD ,_, and_CC for_IN vaccine_NN efficacies_NNS 
          VE_NNP
          S_NNP =_SYM 0_CD ._. 67_CD ,_, 0_CD ._. 8_CD ,_, and_CC 0_CD ._. 9_CD ._. The_DT power_NN analysis_NN outlined_VBN above_IN was_VBD
          implemented_VBN in_IN the_DT R_NNP Language_NNP of_IN Statistical_NNP Computing_NNP [_NN 25_CD ]_NN ._. An_DT R-_NNP script_NN that_WDT performs_VBZ
          the_DT power_NN analysis_NN presented_VBN here_RB is_VBZ provided_VBN as_IN Protocol_NNP S_NNP 1_CD ._.
          For_IN large_JJ numbers_NNS of_IN animals_NNS per_IN group_NN ,_, 
          n_NN ,_, the_DT statistical_JJ power_NN can_MD be_VB approximated_JJ using_VBG asymptotic_JJ theory_NN ._.
          For_IN the_DT single_JJ low-dose_JJ challenge_NN design_NN the_DT power_NN is_VBZ approximately_RB (_( e_SYM ._. g_SYM ._. ,_, [_NN 26_CD ]_NN ,_, p_NN ._.
          240_CD )_) :_:
          
          Hereby_NNP ,_, Φ_NN denotes_NNS the_DT cumulative_JJ normal_JJ distribution_NN ,_,
          
          and_CC 
          z_SYM
          α_NN is_VBZ the_DT standard_JJ normal_JJ deviate_NN associated_VBN with_IN the_DT one-tailed_JJ
          probability_NN α_NN (_( the_DT significance_NN level_NN )_) ._. Furthermore_RB ,_, 
          p_NN
          c_SYM and_CC 
          p_NN
          v_NN denote_NN the_DT infection_NN probabilities_NNS of_IN animals_NNS in_IN the_DT control_NN
          and_CC vaccinated_JJ groups_NNS ,_, respectively_RB ,_, and_CC 
          n_NN the_DT number_NN of_IN animals_NNS per_IN group_NN ._. The_DT term_NN 1_CD /_NN
          n_NN in_IN the_DT numerator_NN is_VBZ the_DT continuity_NN correction_NN [_NN 27_CD ,_, 28_CD ]_NN ._.
          For_IN the_DT repeated_VBN low-dose_JJ challenge_NN design_NN ,_, the_DT number_NN of_IN challenges_NNS is_VBZ not_RB the_DT same_JJ
          as_IN the_DT number_NN of_IN animals_NNS ,_, 
          n_NN ,_, but_CC is_VBZ a_DT random_JJ variable_NN ._. The_DT number_NN of_IN challenges_NNS for_IN each_DT
          individual_NN is_VBZ geometrically_RB distributed_VBN with_IN a_DT maximum_NN of_IN 
          C_NNP
          max_NN ._. The_DT expected_VBN number_NN of_IN challenges_NNS in_IN the_DT control_NN group_NN ,_, ,_,
          and_CC the_DT vaccinated_JJ group_NN ,_, are_VBP
          
          and_CC
          
          Substituting_VBG the_DT expected_VBN number_NN of_IN challenges_NNS for_IN the_DT actual_JJ number_NN ,_, we_PRP can_MD
          approximate_JJ the_DT statistical_JJ power_NN of_IN the_DT repeated_VBN low-dose_JJ challenge_NN design_NN as_IN
          
          Hereby_NNP ,_, γ_NN =_SYM (_( 1_CD /_NN 〈_NN η_NN
          c_SYM 〉_NN +_NN 1_CD /_NN 〈_NN η_NN
          v_NN 〉_NN )_) /_NN 2_CD is_VBZ the_DT continuity_NN correction_NN ._. For_IN 
          C_NNP
          max_NN =_SYM 1_CD ,_, equation_NN 17_CD reduces_VBZ to_TO equation_NN 13_CD ._. Because_IN the_DT
          approximation_NN in_IN equation_NN 17_CD involves_VBZ the_DT substitution_NN of_IN a_DT random_JJ variable_NN with_IN its_PRP$
          expectation_NN ,_, it_PRP is_VBZ less_RBR accurate_JJ than_IN the_DT approximation_NN for_IN the_DT power_NN of_IN the_DT single_JJ
          low-dose_JJ challenge_NN design_NN in_IN equation_NN 13_CD ._. The_DT R-_NNP script_NN provided_VBN as_IN Protocol_NNP S_NNP 1_CD also_RB
          contains_VBZ a_DT function_NN that_WDT calculates_VBZ the_DT statistical_JJ power_NN using_VBG equation_NN 17_CD ._.
        
      
      
        Results_NNS
        
          Single_NNP Low-_NNP Dose_NNP Challenge_NNP Design_NNP Requires_NNP Large_JJ Numbers_NNPS of_IN Animals_NNS
          How_WRB would_MD we_PRP measure_VB protection_NN against_IN infection_NN in_IN a_DT low-dose_JJ challenge_NN model_NN ?_. The_DT
          most_RBS straight-forward_JJ design_NN would_MD involve_VB a_DT large_JJ number_NN of_IN hosts_NNS ,_, some_DT vaccinated_JJ and_CC
          some_DT unvaccinated_JJ ._. After_IN challenge_NN with_IN a_DT low_JJ dose_NN ,_, one_PRP would_MD determine_VB the_DT fraction_NN of_IN
          infected_JJ hosts_NNS in_IN vaccinated_JJ and_CC unvaccinated_JJ groups_NNS ,_, and_CC assess_VB whether_IN there_EX is_VBZ a_DT
          statistically_RB significant_JJ difference_NN in_IN the_DT fractions_NNS (_( see_VB Figure_NN 1_CD A_DT )_) ._.
          To_TO assess_VB how_WRB many_JJ animals_NNS would_MD be_VB required_VBN in_IN a_DT single_JJ low-dose_JJ challenge_NN
          experiment_NN ,_, we_PRP performed_VBD a_DT statistical_JJ power_NN analysis_NN (_( see_VB Methods_NNP )_) ._. The_DT statistical_JJ
          power_NN of_IN an_DT experimental_JJ design_NN is_VBZ defined_VBN as_IN the_DT probability_NN that_IN ,_, in_IN an_DT experiment_NN with_IN
          an_DT effective_JJ vaccine_NN ,_, the_DT vaccine_NN is_VBZ correctly_RB determined_VBN to_TO be_VB effective_JJ ._. Obviously_RB the_DT
          power_NN depends_VBZ on_IN the_DT efficacy_NN of_IN the_DT vaccine_NN (_( which_WDT is_VBZ called_VBN the_DT “ effect_NN size_NN” in_IN the_DT
          context_NN of_IN power_NN analysis_NN )_) and_CC the_DT number_NN of_IN host_NN animals_NNS used_VBN in_IN the_DT experiment_NN ._. In_IN the_DT
          power_NN analysis_NN we_PRP performed_VBD ,_, we_PRP assumed_VBD that_IN we_PRP had_VBD equal_JJ numbers_NNS of_IN unvaccinated_JJ and_CC
          vaccinated_JJ animals_NNS ,_, and_CC that_IN all_DT animals_NNS within_IN a_DT group_NN were_VBD equally_RB susceptible_JJ to_TO
          infection_NN ._. Lastly_NNP ,_, we_PRP assumed_VBD that_IN the_DT vaccine_NN was_VBD “ leaky_JJ” [_NN 29_CD ,_, 30_CD ]_NN ,_, i_NNP ._. e_SYM ._. ,_, that_IN the_DT
          susceptibility_NN of_IN vaccinated_JJ animals_NNS was_VBD by_IN a_DT constant_JJ factor_NN lower_JJR than_IN the_DT
          susceptibility_NN of_IN the_DT unvaccinated_JJ control_NN animals_NNS ._.
          In_IN virtual_JJ experiments_NNS ,_, we_PRP then_RB challenged_VBD each_DT (_( virtual_JJ )_) animal_NN once_RB with_IN a_DT challenge_NN
          dose_NN of_IN one_CD 
          ID_NNP
          50_CD ,_, the_DT dose_NN at_IN which_WDT on_IN average_JJ 50_CD %_NN of_IN the_DT unvaccinated_JJ animals_NNS
          become_VBP infected_JJ after_IN a_DT single_JJ challenge_NN ._. Using_VBG a_DT one-sided_JJ Fisher_NNP 's_POS exact_JJ test_NN ,_, we_PRP
          tested_VBD whether_IN the_DT fraction_NN of_IN infected_JJ animals_NNS in_IN the_DT vaccinated_JJ group_NN was_VBD significantly_RB
          lower_JJR than_IN in_IN the_DT control_NN group_NN ._. Performing_VBG 100_CD ,_, 000_CD such_JJ virtual_JJ experiments_NNS for_IN a_DT given_VBN
          number_NN 
          n_NN animals_NNS per_IN group_NN ,_, we_PRP estimated_VBD the_DT statistical_JJ power_NN as_IN the_DT fraction_NN
          of_IN virtual_JJ experiments_NNS that_WDT yielded_VBD significant_JJ results_NNS (_( significance_NN level_NN α_NN =_SYM
          0_CD ._. 05_CD )_) ._.
          The_DT result_NN of_IN this_DT power_NN analysis_NN is_VBZ shown_VBN by_IN the_DT green_JJ curves_NNS in_IN Figure_NN 2_CD ._. We_PRP
          calculated_VBD the_DT power_NN for_IN vaccine_NN efficacies_NNS of_IN 67_CD %_NN ,_, 80_CD %_NN ,_, and_CC 90_CD %_NN ._. We_PRP found_VBD that_IN ,_, even_RB for_IN
          the_DT highest_JJS vaccine_NN efficacy_NN of_IN 90_CD %_NN ,_, the_DT single_JJ low-dose_JJ challenge_NN design_NN required_VBN more_JJR
          than_IN 20_CD animals_NNS per_IN group_NN to_TO reach_VB a_DT statistical_JJ power_NN of_IN 95_CD %_NN ._. Thus_RB ,_, the_DT single_JJ low-dose_JJ
          challenge_NN design_NN is_VBZ not_RB feasible_JJ ,_, or_CC at_IN least_JJS not_RB practical_JJ ,_, to_TO assess_VB the_DT efficacy_NN of_IN a_DT
          vaccine_NN or_CC other_JJ preventive_JJ interventions_NNS in_IN animals_NNS ._.
        
        
          Repeated_NNP Low-_NNP Dose_NNP Challenge_NNP Design_NNP Does_VBZ Not_RB Require_VB Large_JJ Numbers_NNPS of_IN Animals_NNS
          We_PRP propose_VBP an_DT alternative_JJ design_NN involving_VBG repeated_VBN challenges_NNS of_IN individual_JJ animals_NNS
          with_IN low_JJ doses_NNS ,_, which_WDT circumvents_VBZ the_DT disadvantage_NN of_IN the_DT single_JJ low-dose_JJ challenge_NN
          design_NN that_IN large_JJ numbers_NNS of_IN host_NN individuals_NNS are_VBP required_VBN ._. Repeated_NNP challenges_NNS
          effectively_RB “ recycle_VB” host_NN animals_NNS ,_, thus_RB increasing_VBG the_DT statistical_JJ power_NN of_IN the_DT
          experiment_NN ._. In_IN addition_NN to_TO increasing_VBG the_DT statistical_JJ power_NN of_IN the_DT experimental_JJ design_NN ,_,
          repeated_VBN challenges_NNS recapitulate_NN much_RB more_RBR realistically_RB the_DT circumstances_NNS of_IN human_JJ
          exposure_NN than_IN single_JJ challenges_NNS ._. In_IN this_DT alternative_JJ design_NN ,_, the_DT efficacy_NN of_IN a_DT vaccine_NN
          can_MD be_VB estimated_VBN by_IN measuring_VBG the_DT difference_NN in_IN the_DT number_NN of_IN challenges_NNS needed_VBN to_TO infect_NN
          vaccinated_JJ versus_CC unvaccinated_JJ hosts_NNS (_( see_VB Figure_NN 1_CD B_NNP )_) ._.
          To_TO show_VB that_IN this_DT alternative_JJ design_NN does_VBZ not_RB require_VB unfeasibly_RB large_JJ numbers_NNS of_IN
          animals_NNS ,_, we_PRP performed_VBD a_DT statistical_JJ power_NN analysis_NN (_( see_VB Methods_NNP )_) ._. As_IN for_IN the_DT single_JJ
          low-dose_JJ design_NN ,_, we_PRP assumed_VBD that_IN we_PRP had_VBD equal_JJ numbers_NNS of_IN unvaccinated_JJ and_CC vaccinated_JJ
          animals_NNS ,_, and_CC that_IN all_DT animals_NNS within_IN a_DT group_NN were_VBD equally_RB susceptible_JJ to_TO infection_NN ._. We_PRP
          further_RBR made_VBD the_DT important_JJ assumption_NN that_IN the_DT susceptibility_NN of_IN an_DT individual_JJ animal_NN was_VBD
          independent_JJ of_IN how_WRB often_RB the_DT animal_NN was_VBD unsuccessfully_RB challenged_VBN previously_RB ._. This_DT
          assumption_NN is_VBZ commonly_RB adopted_VBN in_IN statistical_JJ models_NNS that_WDT are_VBP used_VBN to_TO estimate_VB the_DT
          transmission_NN rate_NN of_IN HIV_NNP [_NN 14_CD –_NN 17_CD ]_NN ._. By_IN making_VBG this_DT assumption_NN ,_, we_PRP ignored_VBD that_IN an_DT
          unsuccessful_JJ challenge_NN may_MD induce_VB some_DT degree_NN of_IN immunity_NN against_IN subsequent_JJ challenges_NNS ._.
          We_PRP would_MD like_VB to_TO emphasize_VB ,_, however_RB ,_, that_IN this_DT assumption_NN is_VBZ not_RB crucial_JJ for_IN our_PRP$
          argument_NN ,_, unless_IN the_DT degree_NN of_IN induced_VBN immunity_NN is_VBZ very_RB high_JJ ._. Lastly_NNP ,_, we_PRP again_RB assumed_VBD
          that_IN the_DT vaccine_NN was_VBD leaky_JJ [_NN 29_CD ,_, 30_CD ]_NN ._.
          In_IN virtual_JJ experiments_NNS ,_, we_PRP then_RB challenged_VBD the_DT (_( virtual_JJ )_) animals_NNS repeatedly_RB with_IN a_DT
          challenge_NN dose_NN of_IN one_CD 
          ID_NNP
          50_CD ._. We_PRP allowed_VBD for_IN a_DT maximum_NN number_NN of_IN 20_CD challenges_NNS of_IN each_DT
          individual_JJ animal_NN ._. Table_NNP 3_CD shows_VBZ the_DT outcome_NN of_IN one_CD such_JJ virtual_JJ experiment_NN ._. We_PRP analyzed_VBD
          the_DT outcome_NN of_IN the_DT virtual_JJ experiments_NNS with_IN a_DT one-tailed_JJ Fisher_NNP 's_POS exact_JJ test_NN (_( see_VB
          Methods_NNP )_) ._. We_PRP again_RB estimated_VBD the_DT statistical_JJ power_NN by_IN performing_VBG 100_CD ,_, 000_CD such_JJ virtual_JJ
          experiments_NNS for_IN a_DT given_VBN number_NN 
          n_NN animals_NNS per_IN group_NN ._.
          Figure_NN 2_CD shows_VBZ the_DT statistical_JJ power_NN of_IN the_DT repeated_VBN low-dose_JJ challenge_NN design_NN as_IN a_DT
          function_NN of_IN the_DT number_NN of_IN animals_NNS per_IN group_NN for_IN varying_VBG vaccine_NN efficacies_NNS (_( black_JJ lines_NNS )_) ,_,
          and_CC compares_VBZ it_PRP to_TO the_DT statistical_JJ power_NN of_IN the_DT single_JJ low-dose_JJ challenge_NN design_NN (_( green_JJ
          lines_NNS )_) ._. The_DT statistical_JJ power_NN achieved_VBN with_IN the_DT repeated_VBN low-dose_JJ challenge_NN design_NN is_VBZ
          generally_RB higher_JJR than_IN that_DT achieved_VBD with_IN the_DT single_JJ low-dose_JJ challenge_NN design_NN ._. If_IN the_DT
          vaccine_NN is_VBZ 90_CD %_NN effective_JJ (_(
          VE_NNP
          S_NNP =_SYM 0_CD ._. 9_CD )_) ,_, i_NNP ._. e_SYM ._. ,_, it_PRP reduces_VBZ the_DT susceptibility_NN by_IN a_DT factor_NN of_IN ten_CD ,_,
          the_DT number_NN of_IN animals_NNS per_IN group_NN could_MD be_VB as_RB low_JJ as_IN five_CD to_TO achieve_VB more_JJR than_IN 95_CD %_NN
          statistical_JJ power_NN ._. In_IN contrast_NN ,_, in_IN single_JJ low-dose_JJ challenge_NN experiments_NNS with_IN the_DT same_JJ
          number_NN of_IN animals_NNS per_IN group_NN the_DT statistical_JJ power_NN is_VBZ only_RB 15_CD %_NN ._. Thus_RB ,_, repeated_VBD low-dose_JJ
          challenge_NN experiments_NNS are_VBP expected_VBN to_TO require_VB far_RB fewer_JJR animals_NNS than_IN single_JJ low-dose_JJ
          challenge_NN experiments_NNS ._.
        
        
          How_WRB Often_RB Should_MD Virus_NNP Challenges_VBZ Be_VB Repeated_NNP ?_.
          To_TO investigate_VB how_WRB the_DT maximum_NN number_NN of_IN challenges_NNS affected_VBD the_DT statistical_JJ power_NN ,_, we_PRP
          plotted_VBD the_DT power_NN against_IN 
          C_NNP
          max_NN for_IN trials_NNS involving_VBG six_CD and_CC 12_CD animals_NNS per_IN group_NN (_( Figure_NN 3_LS )_) ._.
          We_PRP found_VBD that_IN the_DT power_NN increases_NNS with_IN 
          C_NNP
          max_NN ,_, but_CC for_IN high_JJ 
          C_NNP
          max_NN the_DT returns_NNS diminished_VBN considerably_RB ._. The_DT lower_VB the_DT number_NN of_IN
          animals_NNS per_IN group_NN ,_, 
          n_NN ,_, the_DT higher_JJR the_DT maximum_NN number_NN of_IN challenges_NNS ,_, 
          C_NNP
          max_NN ,_, for_IN which_WDT the_DT power_NN effectively_RB saturated_VBD ._. Even_RB for_IN low_JJ
          numbers_NNS of_IN animals_NNS per_IN group_NN ,_, 
          n_NN ,_, however_RB ,_, the_DT maximum_NN number_NN of_IN challenges_NNS ,_, 
          C_NNP
          max_NN ,_, needed_VBN to_TO unfold_VB the_DT full_JJ potential_NN of_IN the_DT repeated_VBN low-dose_JJ
          challenge_NN design_NN was_VBD in_IN a_DT feasible_JJ range_NN ._.
        
        
          Impact_NNP of_IN Animal-to-_NNP Animal_NNP Variation_NNP in_IN Susceptibility_NNP
          To_TO study_VB how_WRB potential_JJ heterogeneity_NN in_IN susceptibility_NN affected_VBD the_DT power_NN of_IN low-dose_JJ
          challenge_NN trials_NNS ,_, we_PRP simulated_JJ experiments_NNS in_IN which_WDT each_DT animal_NN was_VBD assigned_VBN an_DT
          individual_JJ infection_NN probability_NN (_( see_VB Methods_NNP )_) ._. In_IN these_DT simulations_NNS ,_, the_DT degree_NN of_IN
          heterogeneity_NN was_VBD measured_VBN by_IN the_DT coefficient_NN of_IN variation_NN ,_, 
          CV_NNP ,_, of_IN the_DT susceptibility_NN distributions_NNS ._. Figure_NN 4_CD A_DT shows_VBZ susceptibility_NN
          distributions_NNS for_IN three_CD different_JJ values_NNS of_IN 
          CV_NNP ._.
          We_PRP extended_VBD our_PRP$ power_NN analysis_NN by_IN considering_VBG the_DT impact_NN of_IN the_DT heterogeneity_NN
          parameter_NN 
          CV_NNP on_IN the_DT statistical_JJ power_NN (_( Figure_NN 4_CD B_NNP )_) ._. We_PRP found_VBD that_IN the_DT statistical_JJ
          power_NN of_IN the_DT single_JJ low-dose_JJ challenge_NN design_NN was_VBD almost_RB unaffected_JJ by_IN animal-to-animal_JJ
          variation_NN in_IN infection_NN probability_NN ,_, whereas_IN ,_, for_IN the_DT repeated_VBN low-dose_JJ challenge_NN design_NN ,_,
          the_DT power_NN decreased_VBD with_IN increasing_VBG heterogeneity_NN ._. Importantly_NNP ,_, however_RB ,_, the_DT power_NN did_VBD
          not_RB decrease_VB linearly_RB with_IN heterogeneity_NN :_: it_PRP was_VBD sufficiently_RB stable_JJ in_IN the_DT range_NN 0_CD <_NN 
          CV_NNP <_NN 0_CD ._. 3_CD and_CC dropped_VBD mainly_RB for_IN 
          CV_NNP >_NN 0_CD ._. 3_CD ._. Thus_RB ,_, over_IN a_DT wide_JJ range_NN of_IN potential_JJ animal-to-animal_JJ
          variation_NN in_IN susceptibility_NN ,_, low-dose_JJ challenge_NN designs_NNS are_VBP sufficiently_RB powered_VBN ,_, and_CC the_DT
          power_NN of_IN the_DT repeated_VBN low-dose_JJ experiments_NNS is_VBZ superior_JJ to_TO that_DT of_IN single_JJ low-dose_JJ
          challenge_NN experiments_NNS ._.
        
      
      
        Discussion_NNP
        Preclinical_NNP studies_NNS assessing_VBG the_DT efficacy_NN of_IN potential_JJ vaccines_NNS ,_, microbicides_NNS ,_, or_CC
        systemic_JJ chemoprophylaxis_NNS are_VBP usually_RB conducted_VBN with_IN very_RB high_JJ virus_NN challenge_NN doses_NNS ,_, which_WDT
        result_VBP in_IN infection_NN with_IN certainty_NN ._. Since_IN these_DT high_JJ challenge_NN doses_NNS do_VBP not_RB reflect_VB the_DT low_JJ
        probability_NN of_IN HIV_NNP transmission_NN in_IN humans_NNS ,_, vaccines_NNS or_CC prophylactic_JJ treatment_NN strategies_NNS
        that_WDT are_VBP effective_JJ against_IN “ real_JJ life_NN” exposures_NNS may_MD go_VB undetected_JJ in_IN high-dose_JJ challenge_NN
        experiments_NNS ._. For_IN example_NN ,_, zidovudine_NN was_VBD found_VBN to_TO prevent_VB a_DT large_JJ fraction_NN of_IN perinatal_NN HIV_NNP
        infections_NNS [_NN 23_CD ]_NN ,_, even_RB though_IN studies_NNS in_IN animal_NN models_NNS ,_, conducted_VBN with_IN high_JJ challenge_NN doses_NNS ,_,
        could_MD not_RB establish_VB any_DT protection_NN against_IN infection_NN by_IN zidovudine_NN [_NN 20_CD –_NN 22_CD ]_NN ._.
        In_IN this_DT paper_NN ,_, we_PRP investigated_VBD how_WRB efficacy_NN trials_NNS of_IN vaccines_NNS and_CC preventive_JJ treatment_NN
        could_MD be_VB conducted_VBN with_IN low_JJ challenge_NN doses_NNS in_IN animal_NN models_NNS ._. We_PRP showed_VBD that_IN the_DT repeated_VBN
        low-dose_JJ challenge_NN design_NN is_VBZ expected_VBN to_TO require_VB far_RB fewer_RBR experimental_JJ animals_NNS than_IN
        commonly_RB believed_VBN ._. It_PRP may_MD therefore_RB be_VB feasible_JJ to_TO conduct_VB trials_NNS with_IN low_JJ challenge_NN doses_NNS ,_,
        which_WDT more_RBR realistically_RB simulate_VBP exposures_NNS of_IN humans_NNS to_TO HIV_NNP ,_, allowing_VBG us_PRP to_TO more_RBR directly_RB
        and_CC sensitively_RB assess_VB vaccine_NN or_CC treatment_NN efficacy_NN than_IN with_IN high-dose_JJ challenge_NN
        experiments_NNS ._.
        Owing_NNP to_TO the_DT concerns_NNS with_IN high_JJ challenge_NN doses_NNS ,_, several_JJ research_NN groups_NNS ,_, including_VBG our_PRP$
        own_JJ ,_, have_VBP started_VBN to_TO develop_VB low-dose_JJ challenge_NN models_NNS [_NN 31_CD –_NN 34_CD ]_NN ._. In_IN these_DT preliminary_JJ
        studies_NNS ,_, infection_NN could_MD be_VB achieved_VBN by_IN challenging_VBG macaques_NNS intra-rectally_JJ [_NN 31_CD ]_NN ,_,
        intra-vaginally_JJ [_NN 32_CD ,_, 34_CD ]_NN ,_, or_CC orally_RB [_NN 33_CD ]_NN ._.
        Since_IN adopting_VBG low-dose_JJ challenge_NN approaches_NNS has_VBZ far-reaching_JJ consequences_NNS for_IN the_DT
        design_NN of_IN efficacy_NN trials_NNS of_IN vaccines_NNS or_CC preventive_JJ treatment_NN in_IN animal_NN models_NNS ,_, we_PRP would_MD
        like_VB to_TO discuss_VB how_WRB some_DT important_JJ aspects_NNS of_IN trial_NN design_NN ,_, such_JJ as_IN transient_JJ infections_NNS ,_,
        the_DT challenge_NN schedule_NN ,_, the_DT route_NN of_IN infection_NN ,_, and_CC the_DT phenotype_NN and_CC dose_NN of_IN the_DT challenge_NN
        strain_NN ,_, should_MD be_VB dealt_VBN with_IN and_CC could_MD be_VB optimized_JJ ._.
        Using_VBG virus_NN challenge_NN doses_NNS that_WDT do_VBP not_RB give_VB rise_NN to_TO infection_NN with_IN certainty_NN ,_, one_CD has_VBZ
        to_TO carefully_RB define_VB what_WP one_CD means_VBZ by_IN successful_JJ infection_NN ._. This_DT question_NN is_VBZ of_IN particular_JJ
        importance_NN in_IN the_DT repeated_VBN low-dose_JJ challenge_NN design_NN ,_, because_IN the_DT efficacy_NN of_IN a_DT preventive_JJ
        intervention_NN is_VBZ estimated_VBN on_IN the_DT basis_NN of_IN the_DT number_NN of_IN challenges_NNS needed_VBN to_TO infect_NN an_DT
        individual_JJ animal_NN ._. Low-dose_NNP challenges_NNS have_VBP been_VBN observed_VBN to_TO give_VB rise_NN to_TO transiently_RB
        detectable_JJ viremia_NN [_NN 32_CD –_NN 34_CD ]_NN ._. Since_IN transient_JJ infection_NN is_VBZ much_RB more_RBR likely_JJ to_TO lead_VB to_TO
        immunization_NN [_NN 35_CD ]_NN ,_, thus_RB leading_VBG to_TO lower_JJR probabilities_NNS of_IN infection_NN in_IN subsequent_JJ
        challenges_NNS ,_, we_PRP suggest_VBP considering_VBG transient_JJ viremia_NN as_IN successful_JJ infection_NN and_CC not_RB to_TO
        re-challenge_JJ animals_NNS that_WDT were_VBD transiently_RB infected_JJ ._.
        The_DT time_NN interval_NN between_IN challenges_NNS is_VBZ also_RB an_DT essential_JJ parameter_NN in_IN the_DT design_NN of_IN
        repeated_VBN low-dose_JJ challenge_NN experiments_NNS ._. In_IN the_DT four_CD ongoing_JJ repeated_VBN low-dose_JJ challenge_NN
        studies_NNS [_NN 31_CD –_NN 34_CD ]_NN ,_, different_JJ approaches_NNS have_VBP been_VBN taken_VBN ,_, with_IN time_NN intervals_NNS ranging_VBG from_IN
        hours_NNS to_TO a_DT week_NN ._. There_EX may_MD be_VB logistical_JJ reasons_NNS for_IN choosing_VBG short_JJ time_NN intervals_NNS between_IN
        challenges_NNS ,_, but_CC from_IN a_DT statistical_JJ standpoint_NN ,_, the_DT time_NN intervals_NNS should_MD be_VB large_JJ enough_RB to_TO
        allow_VB the_DT identification_NN of_IN the_DT challenge_NN that_WDT gives_VBZ rise_NN to_TO infection_NN ._. Otherwise_RB ,_, the_DT
        statistical_JJ power_NN of_IN the_DT experimental_JJ design_NN will_MD be_VB suboptimal_NN and_CC a_DT beneficial_JJ effect_NN of_IN
        the_DT vaccine_NN candidate_NN may_MD be_VB missed_VBN ._.
        In_IN parallel_JJ to_TO using_VBG more_RBR realistic_JJ ,_, lower_JJR challenge_NN doses_NNS ,_, other_JJ crucial_JJ parameters_NNS of_IN
        the_DT experimental_JJ infection_NN process_NN ,_, such_JJ as_IN the_DT route_NN of_IN transmission_NN and_CC the_DT coreceptor_NN
        usage_NN of_IN the_DT challenge_NN virus_NN ,_, should_MD also_RB be_VB chosen_VBN to_TO be_VB as_RB realistic_JJ as_IN possible_JJ ._. Thus_RB ,_,
        we_PRP propose_VBP infecting_VBG intra-vaginally_JJ or_CC intra-rectally_JJ in_IN experiments_NNS that_WDT aim_NN to_TO assess_VB a_DT
        vaccine_NN or_CC prophylactic_JJ treatment_NN against_IN sexual_JJ transmission_NN of_IN HIV_NNP ._. Further_RB ,_, we_PRP suggest_VBP
        using_VBG challenge_NN viruses_NNS that_WDT utilize_VB CCR_NNP 5_CD as_IN coreceptor_NN ,_, such_JJ as_IN for_IN example_NN SHIV-SF_NNP 162_CD P_NN
        [_NN 36_CD ]_NN ,_, rather_RB than_IN the_DT standard_JJ strain_NN SHIV_NNP 89_CD ._. 6_CD P_NN ,_, which_WDT has_VBZ been_VBN found_VBN to_TO use_VB mainly_RB CXCR_NNP 4_CD
        [_NN 37_CD ,_, 38_CD ]_NN ._. These_DT more_RBR realistic_JJ choices_NNS of_IN the_DT route_NN of_IN infection_NN and_CC coreceptor_NN usage_NN will_MD
        permit_VB the_DT assessment_NN of_IN the_DT efficacy_NN of_IN the_DT preventive_JJ intervention_NN in_IN a_DT setting_VBG that_IN more_RBR
        accurately_RB reflects_VBZ HIV_NNP exposures_NNS of_IN humans_NNS ,_, and_CC will_MD enable_VB us_PRP to_TO carefully_RB investigate_VB
        the_DT processes_NNS that_WDT give_VBP rise_NN to_TO infection_NN ._.
        The_DT challenge_NN dose_NN in_IN a_DT low-dose_JJ challenge_NN study_NN is_VBZ another_DT parameter_NN of_IN crucial_JJ
        importance_NN ._. Although_IN the_DT most_RBS realistic_JJ choice_NN would_MD be_VB a_DT challenge_NN dose_NN that_WDT gives_VBZ rise_NN to_TO
        infection_NN with_IN a_DT probability_NN of_IN approximately_RB 0_CD ._. 0005_CD –_NN 0_CD ._. 10_CD [_NN 14_CD –_NN 17_CD ]_NN ,_, such_JJ extremely_RB low_JJ doses_NNS
        would_MD require_VB unfeasibly_RB large_JJ numbers_NNS of_IN repeated_VBN challenges_NNS per_IN animal_NN ._. Moreover_RB ,_, there_EX
        is_VBZ substantial_JJ variation_NN in_IN transmission_NN rates_NNS due_JJ to_TO differences_NNS in_IN factors_NNS such_JJ as_IN virus_NN
        load_NN or_CC the_DT presence_NN of_IN other_JJ infections_NNS of_IN the_DT genital_JJ tract_NN [_NN 15_CD –_NN 18_CD ]_NN ,_, and_CC theoretical_JJ
        studies_NNS suggest_VBP that_IN preventing_VBG the_DT transmission_NN events_NNS that_WDT occur_VBP with_IN higher_JJR probability_NN
        would_MD have_VB a_DT disproportionately_RB large_JJ effect_NN on_IN controlling_VBG the_DT epidemic_NN [_NN 39_CD ]_NN ._. To_TO maximize_VB
        their_PRP$ epidemiological_JJ relevance_NN ,_, low-dose_JJ challenge_NN experiments_NNS should_MD therefore_RB involve_VB
        challenge_NN doses_NNS that_WDT reflect_VBP transmission_NN probabilities_NNS at_IN the_DT upper_JJ end_NN of_IN the_DT spectrum_NN ._.
        As_IN a_DT compromise_NN between_IN the_DT practicality_NN of_IN high_JJ doses_NNS and_CC the_DT sensitivity_NN associated_VBN with_IN
        realistically_RB low_JJ doses_NNS ,_, we_PRP propose_VBP the_DT 
        ID_NNP
        50_CD ._. The_DT 
        ID_NNP
        50_CD can_MD be_VB estimated_VBN using_VBG well-established_JJ nonparametric_JJ methods_NNS like_IN
        Spearman-_NNP Kärber_NNP [_NN 40_CD ]_NN or_CC single-parameter_JJ methods_NNS [_NN 41_CD ]_NN ,_, and_CC there_EX is_VBZ software_NN available_JJ ,_,
        such_JJ as_IN a_DT freely_RB distributed_VBN package_NN called_VBD ID_NNP 50_CD developed_VBN by_IN John_NNP Spouge_NNP
        (_( http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN CBBresearch_NNP /_NN Spouge_NNP /_NN Virology_NNP /_NN ,_, which_WDT allows_VBZ an_DT automated_VBN
        estimation_NN of_IN the_DT 
        ID_NNP
        50_CD from_IN data_NNS generated_VBN in_IN titration_NN experiments_NNS ._.
        The_DT inability_NN to_TO detect_VB sterilizing_VBG immunity_NN in_IN high-dose_JJ challenge_NN experiments_NNS led_VBN to_TO a_DT
        shift_NN of_IN focus_NN towards_IN indirect_JJ effects_NNS of_IN vaccine_NN candidates_NNS on_IN the_DT pathogenicity_NN of_IN the_DT
        infection_NN and_CC the_DT infectiousness_NNS of_IN the_DT vaccinee_NN ._. This_DT shift_NN of_IN focus_NN required_VBN the_DT
        development_NN of_IN novel_NN statistical_JJ models_NNS that_WDT allowed_VBD the_DT estimation_NN of_IN these_DT indirect_JJ
        effects_NNS [_NN 42_CD ,_, 43_CD ]_NN ._. Will_MD the_DT estimation_NN of_IN vaccine_NN efficacy_NN in_IN repeated_VBN low-dose_JJ challenge_NN
        studies_NNS also_RB require_VBP the_DT development_NN of_IN novel_NN statistical_JJ techniques_NNS ?_. The_DT answer_NN to_TO this_DT
        question_NN depends_VBZ on_IN how_WRB much_JJ the_DT realities_NNS of_IN the_DT infection_NN process_NN deviate_NN from_IN our_PRP$
        idealized_JJ model_NN ._. There_EX are_VBP three_CD potential_JJ deviations_NNS ._. First_LS ,_, we_PRP assumed_VBD in_IN large_JJ parts_NNS of_IN
        this_DT study_NN that_IN the_DT susceptibilities_NNS to_TO infection_NN were_VBD equal_JJ for_IN all_DT animals_NNS within_IN each_DT
        group_NN ._. This_DT is_VBZ almost_RB certainly_RB not_RB the_DT case_NN ._. Although_IN we_PRP have_VBP shown_VBN that_IN low-dose_JJ
        challenge_NN experiments_NNS are_VBP sufficiently_RB powered_VBN even_RB if_IN there_EX is_VBZ substantial_JJ
        animal-to-animal_JJ variation_NN in_IN susceptibility_NN ,_, we_PRP did_VBD not_RB develop_VB the_DT statistical_JJ techniques_NNS
        that_WDT would_MD allow_VB the_DT estimation_NN of_IN this_DT variation_NN ._. The_DT extent_NN of_IN animal-to-animal_JJ variation_NN
        in_IN susceptibility_NN can_MD ,_, in_IN principle_NN ,_, be_VB estimated_VBN ,_, but_CC this_DT will_MD probably_RB require_VB larger_JJR
        numbers_NNS of_IN animals_NNS than_IN the_DT estimation_NN of_IN vaccine_NN efficacy_NN ._. Second_JJ ,_, the_DT vaccine_NN may_MD affect_VB
        the_DT susceptibility_NN of_IN individual_JJ animals_NNS differently_RB ._. While_IN we_PRP assumed_VBD in_IN the_DT present_JJ study_NN
        that_IN the_DT vaccine_NN is_VBZ leaky_JJ ,_, i_NNP ._. e_SYM ._. ,_, that_IN the_DT susceptibility_NN is_VBZ reduced_VBN by_IN a_DT constant_JJ factor_NN in_IN
        each_DT animal_NN ,_, other_JJ modes_NNS of_IN action_NN of_IN a_DT vaccine_NN are_NN possible_JJ ._. In_IN particular_JJ ,_, some_DT animals_NNS
        could_MD be_VB completely_RB protected_VBN by_IN vaccination_NN ,_, while_IN others_NNS may_MD remain_VB completely_RB
        susceptible_JJ ._. This_DT mode_NN of_IN action_NN is_VBZ referred_VBN to_TO as_IN all-or-none_JJ [_NN 29_CD ,_, 30_CD ]_NN ._. Statistical_NNP methods_NNS
        based_VBN on_IN maximum_NN likelihood_NN approaches_NNS exist_VBP that_WDT allow_VBP the_DT determination_NN of_IN the_DT mode_NN of_IN
        action_NN of_IN a_DT given_VBN vaccine_NN ._. However_RB ,_, these_DT methods_NNS are_VBP based_VBN on_IN large_JJ sample_NN asymptotics_NNS ,_,
        and_CC exact_JJ methods_NNS will_MD have_VB to_TO be_VB developed_VBN to_TO analyze_VB the_DT outcome_NN of_IN low-dose_JJ challenge_NN
        experiments_NNS that_WDT involve_VBP small_JJ numbers_NNS of_IN animals_NNS ._. Last_JJ ,_, it_PRP will_MD have_VB to_TO be_VB determined_VBN
        whether_IN the_DT probability_NN of_IN infection_NN changes_NNS with_IN the_DT number_NN of_IN challenges_NNS performed_VBN in_IN a_DT
        given_VBN animal_NN ,_, or_CC ,_, to_TO put_VB it_PRP differently_RB ,_, whether_IN the_DT animal_NN has_VBZ a_DT “ memory_NN” of_IN previous_JJ
        challenges_NNS ._. In_IN our_PRP$ analysis_NN ,_, we_PRP assumed_VBD that_IN the_DT susceptibility_NN of_IN an_DT animal_NN did_VBD not_RB change_VB
        from_IN challenge_NN to_TO challenge_VB ._. If_IN the_DT probability_NN of_IN infection_NN changes_NNS significantly_RB with_IN the_DT
        number_NN of_IN challenges_NNS ,_, however_RB ,_, the_DT development_NN of_IN novel_NN statistical_JJ models_NNS that_WDT take_VBP such_JJ
        changes_NNS into_IN account_NN will_MD be_VB necessary_JJ to_TO adequately_RB estimate_VB vaccine_NN efficacy_NN ._.
        In_IN addition_NN to_TO the_DT potential_NN to_TO assess_VB the_DT vaccine_NN or_CC microbicide_NN efficacy_NN more_RBR
        sensitively_RB and_CC in_IN a_DT more_RBR realistic_JJ setting_NN ,_, a_DT low-dose_JJ challenge_NN approach_NN may_MD enable_VB us_PRP to_TO
        answer_VB questions_NNS that_WDT cannot_NN even_RB be_VB asked_VBN in_IN high-dose_JJ challenge_NN models_NNS ._. Some_DT of_IN the_DT most_RBS
        relevant_JJ of_IN these_DT questions_NNS relate_VBP to_TO the_DT effect_NN of_IN challenges_NNS that_WDT do_VBP not_RB lead_VB to_TO
        infection_NN ._. If_IN a_DT low-dose_JJ challenge_NN does_VBZ not_RB give_VB rise_NN to_TO infection_NN ,_, where_WRB was_VBD the_DT virus_NN
        blocked_VBN ?_. Did_VBD the_DT virus_NN fail_VB to_TO establish_VB an_DT infection_NN at_IN all_DT ?_. Or_CC did_VBD it_PRP replicate_VB
        transiently_RB ,_, but_CC was_VBD cleared_VBN by_IN the_DT host_NN 's_POS immunity_NN ?_. And_CC ,_, very_RB importantly_RB ,_, is_VBZ an_DT
        unsuccessfully_RB challenged_VBN animal_NN partially_RB immunized_JJ against_IN further_JJ challenges_NNS ,_, or_CC ,_,
        alternatively_RB ,_, do_VBP unsuccessful_JJ challenges_NNS facilitate_VBP future_JJ infection_NN by_IN “ seeding_VBG” animals_NNS
        with_IN defective_JJ proviruses_NNS that_WDT may_MD recombine_NN with_IN complementing_VBG viruses_NNS upon_IN subsequent_JJ
        exposures_NNS [_NN 44_CD ]_NN ?_.
        The_DT answers_NNS to_TO these_DT questions_NNS would_MD greatly_RB enhance_VB our_PRP$ understanding_NN of_IN HIV_NNP
        transmission_NN and_CC pathogenesis_NNS ,_, and_CC thus_RB would_MD provide_VB further_JJ guidance_NN toward_IN an_DT effective_JJ
        vaccine_NN or_CC microbicide_NN ._. Furthermore_RB ,_, by_IN assessing_VBG the_DT protection_NN against_IN infection_NN
        directly_RB ,_, we_PRP may_MD be_VB able_JJ to_TO discern_VB the_DT specific_JJ types_NNS and_CC levels_NNS of_IN vaccine-induced_JJ
        cellular_JJ and_CC humoral_NN immune_JJ responses_NNS associated_VBN with_IN sterilizing_VBG immunity_NN [_NN 13_CD ]_NN ._. This_DT would_MD
        provide_VB important_JJ benchmarks_NNS by_IN which_WDT to_TO judge_VB new_JJ vaccine_NN candidates_NNS ,_, and_CC could_MD also_RB allow_VB
        retrospective_NN analysis_NN of_IN vaccine_NN candidates_NNS evaluated_VBN earlier_RBR in_IN high-dose_JJ challenge_NN
        studies_NNS ._.
        In_IN conclusion_NN ,_, the_DT repeated_VBN low-dose_JJ challenge_NN approach_NN may_MD enable_VB us_PRP to_TO assess_VB the_DT
        potential_JJ efficacy_NN of_IN vaccines_NNS and_CC prophylactic_JJ treatment_NN strategies_NNS more_RBR realistically_RB ,_,
        and_CC more_RBR sensitively_RB than_IN the_DT standard_JJ high-dose_JJ challenge_NN approach_NN ._. The_DT increased_VBN
        sensitivity_NN may_MD allow_VB us_PRP to_TO more_RBR rapidly_RB identify_VB interventions_NNS that_WDT significantly_RB reduce_VB
        the_DT transmission_NN of_IN low-dose_JJ infections_NNS that_WDT characterize_VBP the_DT natural_JJ spread_NN of_IN HIV_NNP ._.
      
      
        Supporting_VBG Information_NNP
      
    
  
